These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7907184)

  • 1. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of neuroleptic-resistant schizophrenic relapse.
    Kinon BJ; Kane JM; Johns C; Perovich R; Ismi M; Koreen A; Weiden P
    Psychopharmacol Bull; 1993; 29(2):309-14. PubMed ID: 7904762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
    Cohen JD; Van Putten T; Marder S; Berger PA; Stahl SM
    J Clin Psychopharmacol; 1987 Oct; 7(5):324-9. PubMed ID: 2890671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
    Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
    Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
    Mazure CM; Cellar JS; Bowers MB; Nelson JC; Takeshita J; Zigun B
    J Clin Psychiatry; 1995 Mar; 56(3):94-100. PubMed ID: 7883736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.
    Taniguchi T; Sumitani S; Aono M; Iga J; Kinouchi S; Aki H; Matsushita M; Taniguchi K; Tsuno M; Yamanishi K; Tomotake M; Kaneda Y; Ohmori T
    Hum Psychopharmacol; 2006 Oct; 21(7):439-45. PubMed ID: 17029303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of clozapine response in schizophrenia.
    Pickar D; Owen RR; Litman RE; Hsiao JK; Su TP
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():129-32. PubMed ID: 7525541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
    Chakos MH; Mayerhoff DI; Loebel AD; Alvir JM; Lieberman JA
    Psychopharmacol Bull; 1992; 28(1):81-6. PubMed ID: 1609046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients.
    Høiberg MP; Nielsen B
    Nord J Psychiatry; 2006; 60(3):207-12. PubMed ID: 16720511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine.
    Gaffney GR; Tune LE
    J Clin Psychiatry; 1985 Oct; 46(10):428-9. PubMed ID: 2864332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients.
    Nedopil N; Pflieger R; Rüther E
    Pharmacopsychiatria; 1983 Nov; 16(6):201-5. PubMed ID: 6141576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
    Singh MM; Kay SR
    Biol Psychiatry; 1979 Apr; 14(2):277-94. PubMed ID: 38865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic induced extrapyramidal symptoms.
    Donlon PT; Stenson RL
    Dis Nerv Syst; 1976 Nov; 37(11):629-35. PubMed ID: 136337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.